{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:15:40Z","timestamp":1790540140914,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,5,24]],"date-time":"2013-05-24T00:00:00Z","timestamp":1369353600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1038\/npp.2013.135","type":"journal-article","created":{"date-parts":[[2013,5,24]],"date-time":"2013-05-24T09:47:06Z","timestamp":1369388826000},"page":"2373-2384","source":"Crossref","is-referenced-by-count":77,"title":["The HIV Antiretroviral Drug Efavirenz has LSD-Like Properties"],"prefix":"10.1038","volume":"38","author":[{"given":"Michael B","family":"Gatch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Kozlenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Qi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques D","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gonz\u00e1lez-Maeso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenner C","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles P","family":"France","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn H","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Schetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,24]]},"reference":[{"key":"BFnpp2013135_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/BF00431945","volume":"77","author":"LM Adams","year":"1982","unstructured":"Adams LM, Geyer MA (1982). LSD-induced alterations of locomotor patterns and exploration in rats. Psychopharmacology (Berl) 77: 179\u2013185.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFnpp2013135_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0278-5846(85)90074-0","volume":"9","author":"LM Adams","year":"1985","unstructured":"Adams LM, Geyer MA (1985). Effects of DOM and DMT in a proposed animal model of hallucinogenic activity. Prog Neuropsychopharmacol Biol Psychiatry 9: 121\u2013132.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFnpp2013135_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1037\/1064-1297.2.3.244","volume":"2","author":"JC Anthony","year":"1994","unstructured":"Anthony JC, Warner LA, Kessler RC (1994). Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the national comorbidity survey. Exp Clin Psychopharmacol 2: 244\u2013268.","journal-title":"Exp Clin Psychopharmacol"},{"issue":"Suppl 1","key":"BFnpp2013135_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1258\/095646203322491824","volume":"14","author":"JR Arribas","year":"2003","unstructured":"Arribas JR (2003). Efavirenz: enhancing the gold standard. Int J STD AIDS 14 (Suppl 1): 6\u201314.","journal-title":"Int J STD AIDS"},{"key":"BFnpp2013135_CR5","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1517\/17425255.4.7.965","volume":"4","author":"BM Best","year":"2008","unstructured":"Best BM, Goicoechea M (2008). Efavirenz\u2014still first-line king? Expert Opin Drug Metab Toxicol 4: 965\u2013972.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"BFnpp2013135_CR6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/jac\/dkq434","volume":"66","author":"BM Best","year":"2011","unstructured":"Best BM, Koopmans PP, Letendre SL, Capparelli EV, Rossi SS, Clifford DB et alCHARTER Group (2011). Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother 66: 354\u2013357.","journal-title":"J Antimicrob Chemother"},{"key":"BFnpp2013135_CR7","first-page":"762","volume":"296","author":"JM Brown","year":"2001","unstructured":"Brown JM, Hanson GR, Fleckenstein AE (2001). Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther 296: 762\u2013767.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2013135_CR8","unstructured":"Central Intelligence Agency (CIA) World Fact Book (2009). Country Comparisons\u2014HIV\/AIDS\u2014adult prevalence rate. Data from 2007 estimates Available at: https:\/\/www.cia.gov\/library\/publications\/the-world-factbook\/rankorder\/2155rank.html ."},{"key":"BFnpp2013135_CR9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2165\/00002018-200629100-00004","volume":"29","author":"MS Cespedes","year":"2006","unstructured":"Cespedes MS, Aberg JA (2006). Neuropsychiatric complications of antiretroviral therapy. Drug Saf 29: 865\u2013874.","journal-title":"Drug Saf"},{"key":"BFnpp2013135_CR10","first-page":"95","volume":"186","author":"AM Cesura","year":"1990","unstructured":"Cesura AM, Bertocci B, Da Prada M (1990). Binding of [3H]dihydrotetrabenazine and [125I]azidoiodoketanserin photoaffinity labeling of the monoamine transporter of platelet 5-HT organelles. Eur J Pharmacol 1990 186: 95\u2013104.","journal-title":"Eur J Pharmacol 1990"},{"key":"BFnpp2013135_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.addbeh.2008.10.021","volume":"34","author":"CY Chen","year":"2009","unstructured":"Chen CY, Storr CL, Anthony JC (2009). Early-onset drug use and risk for drug dependence problems. Addict Behav 34: 319\u2013322.","journal-title":"Addict Behav"},{"key":"BFnpp2013135_CR12","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/nprot.2006.279","volume":"1","author":"CL Cunningham","year":"2006","unstructured":"Cunningham CL, Gremel CM, Groblewski PA (2006). Drug-induced conditioned place preference and aversion in mice. Nat Protoc 1: 1662\u20131670.","journal-title":"Nat Protoc"},{"key":"BFnpp2013135_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.7326\/0003-4819-137-5_Part_2-200209031-00001","volume":"137","author":"M Dybul","year":"2002","unstructured":"Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK, Panel on Clinical Practices for Treatment of HIV (2002). Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 137: 381\u2013433.","journal-title":"Ann Intern Med"},{"key":"BFnpp2013135_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1124\/jpet.108.141531","volume":"328","author":"SS Ericksen","year":"2009","unstructured":"Ericksen SS, Cummings DF, Weinstein H, Schetz JA (2009). Ligand selectivity of D2 dopamine receptors is modulated by changes in local dynamics produced by sodium binding. J Pharm Exp Ther 328: 40\u201354.","journal-title":"J Pharm Exp Ther"},{"key":"BFnpp2013135_CR15","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.1073\/pnas.93.10.5166","volume":"93","author":"JD Erickson","year":"1996","unstructured":"Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E (1996). Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 93: 5166\u20135171.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFnpp2013135_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pbb.2005.12.015","volume":"83","author":"WE Fantegrossi","year":"2006","unstructured":"Fantegrossi WE, Harrington AW, Kiessel CL, Eckler JR, Rabin RA, Winter JC et al (2006). Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacol Biochem Behav 83: 122\u2013129.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFnpp2013135_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bcp.2007.07.018","volume":"75","author":"WE Fantegrossi","year":"2008","unstructured":"Fantegrossi WE, Murnane KS, Reissig CJ (2008). The behavioral pharmacology of hallucinogens. Biochem Pharmacol 75: 17\u201333.","journal-title":"Biochem Pharmacol"},{"key":"BFnpp2013135_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/BF02246074","volume":"121","author":"D Fiorella","year":"1995","unstructured":"Fiorella D, Rabin RA, Winter JC (1995). The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis. Psychopharmacology (Berl) 121: 347\u2013356.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFnpp2013135_CR19","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00213-009-1501-z","volume":"204","author":"MB Gatch","year":"2009","unstructured":"Gatch MB, Rutledge M, Carbonaro T, Forster MJ (2009). Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats. Psychopharmacology 204: 715\u2013724.","journal-title":"Psychopharmacology"},{"key":"BFnpp2013135_CR20","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","volume":"35","author":"RA Glennon","year":"1984","unstructured":"Glennon RA, Titeler M, McKenney JD (1984). Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35: 2505\u20132511.","journal-title":"Life Sci"},{"key":"BFnpp2013135_CR21","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1124\/jpet.109.151142","volume":"329","author":"LA Gonzalez","year":"2009","unstructured":"Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH (2009). Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther 329: 827\u2013837.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFnpp2013135_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","volume":"53","author":"J Gonz\u00e1lez-Maeso","year":"2007","unstructured":"Gonz\u00e1lez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R et al (2007). Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53: 439\u2013452.","journal-title":"Neuron"},{"key":"BFnpp2013135_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature06612","volume":"452","author":"J Gonzalez-Maeso","year":"2008","unstructured":"Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF et al (2008). Identification of a serotonin\/glutamate receptor complex implicated in psychosis. Nature 452: 93\u201397.","journal-title":"Nature"},{"key":"BFnpp2013135_CR24","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1056\/NEJMoa031772","volume":"350","author":"RM Gulick","year":"2004","unstructured":"Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA et al (2004). Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment. N Engl J Med 350: 1850\u20131861.","journal-title":"N Engl J Med"},{"key":"BFnpp2013135_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0896-6273(00)80712-6","volume":"22","author":"R Grailhe","year":"1999","unstructured":"Grailhe R, Waeber C, Dulawa SC, Hornung JP, Zhuang X, Brunner D et al (1999). Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(5A) receptor. Neuron 22: 581\u2013591.","journal-title":"Neuron"},{"key":"BFnpp2013135_CR26","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1086\/497835","volume":"41","author":"F Guti\u00e9rrez","year":"2005","unstructured":"Guti\u00e9rrez F, Navarro A, Padilla S, Ant\u00f3n R, Masi\u00e1 M, Borr\u00e1s J et al (2005). Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 41: 1648\u20131653.","journal-title":"Clin Infect Dis"},{"key":"BFnpp2013135_CR27","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1038\/npp.2009.29","volume":"34","author":"AL Halberstadt","year":"2009","unstructured":"Halberstadt AL, van der Heijden I, Ruderman MA, Risbrough VB, Powell SB (2009). 5-HT2A and 5-HT2C receptors exert opposing effects on locomotor activity in mice (2009). Neuropsychopharmacology 34: 1958\u20131967.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2013135_CR28","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jama.300.5.555","volume":"300","author":"SM Hammer","year":"2008","unstructured":"Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S et al (2008). International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300: 555\u2013570.","journal-title":"JAMA"},{"key":"BFnpp2013135_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2210-6-6","volume":"6","author":"DD Han","year":"2006","unstructured":"Han DD, Gu HH (2006). Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6: 7.","journal-title":"BMC Pharmacol"},{"key":"BFnpp2013135_CR30","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.neuropharm.2010.03.006","volume":"58","author":"RQ Huang","year":"2010","unstructured":"Huang RQ, Singh M, Dillon GH (2010). Genistein directly inhibits NMDA receptors in mouse hippocampal neurons. Neuropharmacology 58: 1246\u20131251.","journal-title":"Neuropharmacology"},{"key":"BFnpp2013135_CR31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1001\/archpsyc.58.4.322","volume":"58","author":"MA Huestis","year":"2001","unstructured":"Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET et al (2001). Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58: 322\u2013328.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2013135_CR32","doi-asserted-by":"publisher","first-page":"7344","DOI":"10.1021\/jm100925m","volume":"53","author":"E Lacivita","year":"2010","unstructured":"Lacivita E, Paola De Giorgio P, Lee IT, Rodeheaver SI, Weiss BA, Fracasso C et al (2010). Design, synthesis, radiolabeling and in vivo evaluation of carbon-11 labeled N-[2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a potential PET tracer for the dopamine D4 receptors. J Med Chem 53: 7344\u20137355.","journal-title":"J Med Chem"},{"key":"BFnpp2013135_CR33","unstructured":"Marwaha A (2008). Getting High on HIV drugs in S Africa, BBC News, 8 December 2008 Available at: http:\/\/news.bbc.co.uk\/2\/hi\/africa\/7768059.stm ."},{"key":"BFnpp2013135_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/BF00426539","volume":"54","author":"HY Meltzer","year":"1977","unstructured":"Meltzer HY, Fessler RG, Simonovic M, Doherty J, Fang VS (1977). Lysergic acid diethylamide: evidence for stimulation of pituitary dopamine receptors. Psychopharmacology (Berl) 54: 39\u201344.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFnpp2013135_CR35","unstructured":"National Research Council (2003) Guidelines for the care and use of mammals in neuroscience and behavioral research. The National Academies Press: Washington, DC."},{"key":"BFnpp2013135_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"DE Nichols","year":"2004","unstructured":"Nichols DE (2004). Hallucinogens. Pharmacol Ther 101: 131\u2013181.","journal-title":"Pharmacol Ther"},{"key":"BFnpp2013135_CR37","first-page":"197","volume":"52","author":"AK Patel","year":"2006","unstructured":"Patel AK, Patel KK (2006). Future implications: compliance and failure with antiretroviral treatment. J Postgrad Med 52: 197\u2013200.","journal-title":"J Postgrad Med"},{"key":"BFnpp2013135_CR38","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1373\/clinchem.2006.067058","volume":"52","author":"S Rossi","year":"2006","unstructured":"Rossi S, Yaksh T, Bentley H, van den Brande G, Grant I, Ellis R (2006). Characterization of interference with 6 commercial delta-9-tetrahydrocannabinol immunoassays by Efavirenz (glucuronide) in urine. Clin Chem 52: 896\u2013898.","journal-title":"Clin Chem"},{"key":"BFnpp2013135_CR39","unstructured":"Sciutto J (2009). ABC World News Report (4 May 2009) Shorten version 6 April 2009: \u2018No Turning Back\u2019: Teens Abuse HIV Drugs. Teens in South Africa Smoke Anti-Retroviral Drug Efavirenz for Cheap High portions archived at http:\/\/www.youtube.com\/watch?v=hjVtthQJnyU ."},{"key":"BFnpp2013135_CR40","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/QAI.0b013e3181cae4a1","volume":"53","author":"J Sierra-Madero","year":"2010","unstructured":"Sierra-Madero J, Villasis-Keever A, M\u00e9ndez P, Mosqueda-G\u00f3mez JL, Torres-Escobar I, Guti\u00e9rrez-Escolano F et al (2010). Prospective, randomized, open label trial of Efavirenz vs Lopinavir\/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell\/mm3 in Mexico. J Acquir Immune Defic Syndr 53: 582\u2013588.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"BFnpp2013135_CR41","first-page":"17","volume":"10","author":"E Vazquez","year":"1999","unstructured":"Vazquez E (1999). Sustiva flashbacks. Posit Aware 10: 17.","journal-title":"Posit Aware"},{"key":"BFnpp2013135_CR42","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MF, B\u00e4bler A, Vogel H, Hell D (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9: 3897\u20133902.","journal-title":"Neuroreport"},{"key":"BFnpp2013135_CR43","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00213-008-1356-8","volume":"203","author":"JC Winter","year":"2009","unstructured":"Winter JC (2009). Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology (Berl) 203: 251\u2013263.","journal-title":"Psychopharmacology (Berl)"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/npp2013135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2013135","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2013135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:44:42Z","timestamp":1684453482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp2013135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,24]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["BFnpp2013135"],"URL":"https:\/\/doi.org\/10.1038\/npp.2013.135","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,24]]}}}